PMID- 36261810
OWN - NLM
STAT- MEDLINE
DCOM- 20221021
LR  - 20240906
IS  - 2662-7671 (Electronic)
IS  - 2662-7671 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Oct 19
TI  - Efficacy and safety of curcuminoids alone in alleviating pain and dysfunction for 
      knee osteoarthritis: a systematic review and meta-analysis of randomized 
      controlled trials.
PG  - 276
LID - 10.1186/s12906-022-03740-9 [doi]
LID - 276
AB  - BACKGROUND: Curcuminoids (CURs) are the principal ingredients of Curcuma longa L. 
      [Zingiberaceae] (CL)-an herbal plant used in east Asia to alleviate pain and 
      inflammation. Thus far, the therapeutic effects of CURs for knee osteoarthritis 
      (OA) uncovered by multiple reviews remained uncertain due to broadly involving 
      trials with different agents-combined or CURs-free interventions. Therefore, we 
      formed stringent selection criteria and assessment methods to summarize current 
      evidence on the efficacy and safety of CURs alone in the treatment of knee OA. 
      METHODS: A series of databases were searched for randomized controlled trials 
      (RCTs) evaluating the efficacy and safety of CURs for knee OA. Clinical outcomes 
      were evaluated using meta-analysis and the minimum clinically important 
      difference (MCID) for both statistical and clinical significance. RESULTS: 
      Fifteen studies with 1670 patients were included. CURs were significantly more 
      effective than placebo in the improvements of VAS for pain ( WMD: - 1.77, 95% 
      CI: - 2.44 to - 1.09), WOMAC total score ( WMD: - 7.06, 95% CI: - 12.27 
      to - 1.84), WOMAC pain score ( WMD: - 1.42, 95% CI: - 2.41 to - 0.43), WOMAC 
      function score ( WMD: - 5.04, 95% CI: - 7.65 to - 2.43), and WOMAC stiffness 
      score ( WMD: - 0.54, 95% CI: - 1.03 to - 0.05). Meanwhile, CURs were not inferior 
      to NSAIDs in the improvements of pain- and function-related outcomes. 
      Additionally, CURs did not significantly increase the incidence of adverse events 
      (AEs) compared with placebo ( RR: 1.03, 95% CI: 0.69 to 1.53, P = 0.899, 
      I(2) = 23.7%) and NSAIDs (RR: 0.71 0.65, 95% CI: 0.57 0.41 to 0.90 1.03). 
      CONCLUSIONS: CURs alone can be expected to achieve considerable analgesic and 
      functional promotion effects for patients with symptomatic knee OA in short term, 
      without inducing an increase of adverse events. However, considering the low 
      quality and substantial heterogeneity of present studies, a cautious and 
      conservative recommendation for broader clinical use of CURs should still be 
      made. Further high-quality studies are necessary to investigate the impact of 
      different dosages, optimization techniques and administration approaches on 
      long-term safety and efficacy of CURs, so as to strengthen clinical decision 
      making for patients with symptomatic knee OA.
CI  - (c) 2022. The Author(s).
FAU - Feng, Jie
AU  - Feng J
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Li, Zhao
AU  - Li Z
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Tian, Linling
AU  - Tian L
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Mu, Panyun
AU  - Mu P
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Hu, Yimei
AU  - Hu Y
AD  - Department of Orthopedics, Affiliated Hospital of Chengdu University of 
      Traditional Chinese Medicine, Chengdu, Sichuan Province, China. 
      huyimei@cdutcm.edu.cn.
FAU - Xiong, Feng
AU  - Xiong F
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
FAU - Ma, Xu
AU  - Ma X
AD  - Department of Clinical Medicine, Chengdu University of Traditional Chinese 
      Medicine, Chengdu, Sichuan Province, China.
LA  - eng
GR  - 2021MS454/Sichuan Provincial Administration of Traditional Chinese Medicine/
GR  - 20-Y14/the special fund for 100 Talents Program of the First Affiliated Hospital 
      of Chengdu University of TCM/
GR  - 030058047/the scientific research promotion plan of "Xinglin Scholars" Discipline 
      Talents of Chengdu University of traditional Chinese Medicine/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20221019
PL  - England
TA  - BMC Complement Med Ther
JT  - BMC complementary medicine and therapies
JID - 101761232
RN  - 0 (Diarylheptanoids)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
SB  - IM
MH  - Humans
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Diarylheptanoids
MH  - Randomized Controlled Trials as Topic
MH  - Pain/drug therapy
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects
PMC - PMC9580113
OTO - NOTNLM
OT  - Clinical effectiveness
OT  - Curcuminoids
OT  - Knee osteoarthritis
OT  - Meta-analysis
OT  - Minimum clinically important difference
OT  - Systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/20 06:00
MHDA- 2022/10/22 06:00
PMCR- 2022/10/19
CRDT- 2022/10/19 23:47
PHST- 2022/06/12 00:00 [received]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2022/10/19 23:47 [entrez]
PHST- 2022/10/20 06:00 [pubmed]
PHST- 2022/10/22 06:00 [medline]
PHST- 2022/10/19 00:00 [pmc-release]
AID - 10.1186/s12906-022-03740-9 [pii]
AID - 3740 [pii]
AID - 10.1186/s12906-022-03740-9 [doi]
PST - epublish
SO  - BMC Complement Med Ther. 2022 Oct 19;22(1):276. doi: 10.1186/s12906-022-03740-9.